Peritoneal dialysis
Conditions
Interventions
Treatment group:Sacubitril/Valsartan
Sponsors
the First Affiliated Hospital of Anhui University of Chinese Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years, male or female; 2. Maintaining peritoneal dialysis for more than 3 months; 3.24 Urine volume >= 400 ml/d; 4. Blood pressure >= 120/70mm Hg.
Exclusion criteria
Exclusion criteria: 1. Myocardial infarction, unstable angina pectoris, cardiovascular reconstruction surgery (such as stent or bypass surgery) or cerebrovascular accident within 6 months before screening, or planning to undergo cardiovascular reconstruction surgery during the trial; 2. Subjects who have previously received kidney transplantation and are currently receiving immunosuppressive therapy; 3. Patients who have used ACEI/ARB drugs or sacubitril-valsartan tablets within 1 month before screening; 4. Severe liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, or alanine aminotransferase or aspartate aminotransferase levels exceeding 2.0 times the upper limit of normal; 5. Alcoholism or drug abuse, cachexia and mental disorders; 6. Patients who use diuretics for a long time; 7. Known allergy or intolerance to sacubitril and valsartan; 8. Have participated in or are participating in other clinical trials one month before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anuria; | — |
Secondary
| Measure | Time frame |
|---|---|
| Residual kidney GFR;Peritoneal and residual kidney kt / V;Peritoneal and residual renal Ccr;All cause death;Incidence of cardiovascular events;N-terminal natriuretic peptide precursor levels;Left ventricular ejection fraction;24-hour mean systolic blood pressure (mmHg) and mean diastolic blood pressure (mmHg);Hemoglobin level;Serum electrolyte level; | — |
Countries
China
Contacts
Public ContactWang Yiping
the First Affiliated Hospital of Anhui University of Chinese Medicine
Outcome results
None listed